Gina Mauro


Combination treatment with durvalumab/vicineum elicits complete responses in high-grade NMIBC

September 11, 2021

“The combination of Vicineum and durvalumab in BCG-unresponsive NMIBC is tolerated well and no new safety signals were identified; the doublet has a similar safety profile to [what is seen with] both agents used individually,” says Sandeep Gurram, MD.